Project Grant R34CA317559
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $319K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Scottsdale, AZ 85259, USA
Similar Awards
- The National Cancer Institute awarded the University of California, Los Angeles $368,156 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate radiation-induced cellular reprogramming in the developing human brain and identify neuroprotective interventions. The research addresses cognitive decline following cranial radiotherapy for brain tumors by testing the hypothesis that radiation drives neural stem and progenitor cells to transdifferentiate into...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $743,809 on June 12, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate a virtual AI-assisted collaborative songwriting intervention for anxiety in people with advanced cancer. The funded work, termed VIRTUOSO (Virtual AI-Assisted Music Therapy for Anxiety Symptoms in People with Advanced Cancer), addresses anxiety affecting one in two people with advanced cancer—a condition...
- The National Cancer Institute awarded Mayo Clinic Jacksonville $163,320 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support radiation oncology leadership and clinical trial integration activities through August 30, 2031. The award funds the principal investigator's national and institutional leadership roles integrating radiation therapy within the National Clinical Trials Network (NCTN) and Mayo Clinic Comprehensive Cancer Center. Deliverables include...
- The National Cancer Institute awarded the University of Rochester $814,967 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate trajectories of neurotoxicity among adolescents and young adults with Hodgkin lymphoma. The award funds research examining long-term neurotoxic effects of cancer therapy—including cancer-related cognitive impairment and peripheral and autonomic neuropathy—in this population despite the absence of central nervous...
- The National Cancer Institute awarded Mayo Clinic Arizona $657,698 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the molecular mechanisms by which TRPS1 (Transcriptional Repressor GATA Binding 1) regulates regulatory T cell phenotype, function, and lineage stability in tumors. The five-year project, extending through May 31, 2031, will employ genetic tools and multi-omic assays to test whether TRPS1 promotes tumor-infiltrating regulatory T cell stability...
- The National Institutes of Health National Cancer Institute awarded Mayo Clinic $659,028 on May 20, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate multi-modality treatment combinations for aggressive Ewing sarcoma with STAG2 loss. The research addresses radiation therapy–induced immunobiological changes in Ewing tumors, focusing on epigenetic reprogramming and immune system activation to enhance radiation response in STAG2-deficient tumors. The recipient's...
- The National Cancer Institute awarded Seattle Children's Hospital $482,624 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research targeting YBX1 to enhance radiation sensitivity in very high-risk medulloblastoma. The project investigates YBX1 inhibition as a means to improve radiation therapy efficacy in pediatric medulloblastoma, particularly in high-risk subgroups including MYC-amplified Group 3 and TP53-mutated Sonic Hedgehog tumors. Current standard...
- The National Institutes of Health National Cancer Institute awarded The Medical College of Wisconsin, Inc. $413,808 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test a stimulation protocol using a wireless cranial implant to induce neuroplasticity and enable safer, more extensive surgical resection of gliomas that infiltrate critical brain regions. The recipient will develop a disruptive stimulation protocol using the FDA-approved Responsive...
- The National Institutes of Health National Cancer Institute awarded the University of Kansas Medical Center Research Institute, Inc. $667,933 on July 6, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate acceptance and commitment therapy (ACT) as an intervention to improve psychological resilience and physical function in patients undergoing allogeneic hematopoietic stem cell transplantation. The project addresses the significant functional and...
- The National Cancer Institute awarded Massachusetts General Hospital $1.611 million on September 12, 2025, under Cancer Treatment Research (CFDA 93.395) to conduct a randomized controlled trial testing the efficacy of SMART3RP-Lymphoma, a virtual, resilience-based group intervention, in improving quality of life and reducing anxiety, depression, and physical symptoms among early post-treatment lymphoma survivors (0–2 years after curative-intent treatment). The study enrolls 254 participants...